Fulcrum Therapeutics Inc Cash Flow Conversion Efficiency
Fulcrum Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.19 Million) by net assets ($198.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fulcrum Therapeutics Inc (2017–2024)
Cash flow conversion efficiency of Fulcrum Therapeutics Inc from 2017 to 2024. This chart illustrates how Fulcrum Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Fulcrum Therapeutics Inc for real-time trading data and today's change.
Fulcrum Therapeutics Inc Cash Flow Conversion Ratio Explained
Fulcrum Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fulcrum Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulcrum Therapeutics Inc ranked by their cash flow conversion efficiency. Also see FULC company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NEOWIZ
KQ:095660
|
0.074x |
|
Q32 Bio Inc
NASDAQ:QTTB
|
-0.029x |
|
Asure Software Inc
NASDAQ:ASUR
|
0.023x |
|
Dimand S.A.
AT:DIMAND
|
N/A |
|
Eaton Vance National Municipal Opportunities Closed Fund
NYSE:EOT
|
0.020x |
|
Yujin Robot Co. Ltd
KQ:056080
|
0.010x |
|
Sam Yung Tradi
KO:002810
|
0.002x |
|
Meter Instruments Co. Ltd
SHE:301006
|
0.029x |
Annual Cash Flow Conversion Efficiency for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Fulcrum Therapeutics Inc from 2017 to 2024. Review FULC free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $243.03 Million | $-2.22 Million | -0.009x | +97.64% |
| 2023-12-31 | $235.19 Million | $-90.97 Million | -0.387x | +20.72% |
| 2022-12-31 | $198.94 Million | $-97.05 Million | -0.488x | -31.50% |
| 2021-12-31 | $211.54 Million | $-78.48 Million | -0.371x | +34.19% |
| 2020-12-31 | $95.18 Million | $-53.66 Million | -0.564x | -24.43% |
| 2019-12-31 | $87.15 Million | $-39.48 Million | -0.453x | -52.60% |
| 2018-12-31 | $76.00 Million | $-22.56 Million | -0.297x | +98.04% |
| 2017-12-31 | $1.32 Million | $-20.07 Million | -15.185x | -- |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more